Contineum Therapeutics
10578 Science Center Drive
Suite 200
San Diego
California
92121
United States
Tel: 8583497880
Website: https://www.contineum-tx.com/
Email: info@pipeline-tx.com
45 articles about Contineum Therapeutics
-
Contineum Therapeutics Announces Pricing of Initial Public Offering - April 05, 2024
4/5/2024
Contineum Therapeutics, Inc. announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share.
-
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
-
Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.
-
Pipeline Therapeutics Changes Name to Contineum Therapeutics to Reflect Expanded Focus on NI&I Therapeutic Indications (Neuroscience, Inflammation and Immunology)
12/13/2023
Pipeline Therapeutics, Inc. (the Company) announced today that it has changed its name to Contineum Therapeutics, Inc. (Contineum).
-
Pipeline Therapeutics to Participate in Upcoming October 2023 Investor Conferences
10/4/2023
Pipeline Therapeutics announced participation in the following upcoming investor conferences.
-
Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences
9/7/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences.
-
Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study
8/1/2023
Pipeline Therapeutics today announced that the first subject was dosed in the Phase 1 clinical trial of PIPE-791 in healthy volunteers.
-
Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791
6/8/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1 clinical trial of PIPE-791 in healthy volunteers.
-
Pipeline Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference
5/25/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that Carmine Stengone, CEO of Pipeline, will present on June 9, 2023 at 12:15pm ET at the 2023 Jefferies Global Healthcare Conference, being held June 7-9, 2023 in New York, NY.
-
Pipeline Therapeutics to Present at the 2023 RBC Global Healthcare Conference
5/4/2023
Pipeline Therapeutics announced that Carmine Stengone, CEO of Pipeline, will present on Tuesday, May 16, 2023 at 4:05 pm ET at the RBC Global Healthcare Conference, being held May 16-17, 2023 in New York, NY.
-
Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307
4/17/2023
Pipeline Therapeutics announced today that it has entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical.
-
Pipeline Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
4/12/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that Carmine Stengone, CEO of Pipeline, will present a company overview on Wednesday, April 19, 2023, at 3 pm ET at the 22nd Annual Needham Virtual Healthcare Conference.
-
Pipeline Therapeutics Announces Participation at the 2023 Stifel CNS Days Conference
3/21/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will participate in virtual one-on-one meetings with investors at the 2023 Stifel CNS Days Conference, being held in a virtual format March 28-29, 2023.
-
Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)
3/6/2023
Pipeline Therapeutics announced today that it will present a poster highlighting the preclinical profile of PIPE-791 at the Glial Biology: Functional Interactions Among Glia and Neurons, a Gordon Research Conference (GRC), being held March 5-10, 2023, in Ventura, CA.
-
Pipeline Therapeutics Announces Participation in the 2022 RBC Capital Markets Healthcare Private Company Virtual Conference
12/1/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that management will participate in the 2022 RBC Capital Markets Healthcare Private Company Virtual Conference.
-
Pipeline Therapeutics to Present Multiple Posters at SFN 2022 Neuroscience Annual Meeting
11/8/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that it will present two posters at the SFN 2022 Neuroscience Annual Meeting, taking place November 12-16, 2022, in San Diego, CA.
-
Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences in November 2022
11/1/2022
Pipeline Therapeutics announced that management will present at the following investor conferences during November 2022.
-
Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences
10/4/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will participate in the following investor conferences during October 2022.
-
Pipeline Therapeutics to Participate in the UBS Virtual Biotechnology Private Company Symposium
9/8/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will participate virtually in the UBS Biotechnology Private Company Symposium, being held September 21-22, 2022.
-
Pipeline Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
5/26/2022
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that company management will present at the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.